A case report of mitotically active ovarian cellular fibroma with minor sex cord elements

Document Type : Case report

Authors

1 Assistant professor, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Resident, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Professor, Department of Obstetrics and Gynecology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction: Mitotically active cellular fibroma (MACF) with Minor Sex Cord Elements is a extremely rare disease. Although imaging helps in the diagnosis to some extent, the final and definitive diagnosis is based on evaluation and histological studies. The main differential diagnosis of this tumor is ovarian fibrosarcoma, which has moderate to severe atypia and a poorer prognosis. In this study, a case of mitotically active ovarian cellular fibroma with minor sex cord elements is reported.
Case presentation: A 41-year-old woman referred to gynecologic clinic with abdominal pain and abnormal uterine bleeding in the form of spotting. Clinical findings had no signs for diagnosis. Serum Tumor markers including CA125 were within normal limit. Ultrasound and computed tomography (CT) were supportive of sex cord stromal tumors. After surgical procedures and pathologic evaluation, the patient was finally diagnosed as MACF with less than 10% sex cord elements.
Conclusion: Differentiating mitotically active cellular fibroma from fibrosarcoma which may have similar histological findings is important to prevent overtreatment of patient with cellular fibroma.

Keywords


  1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. Lyon, France: International Agency for Research on Cancer. World Health Organization Classification of Tumours 2014; 6.
  2. Sun TT, Cheng NH, Cao DY, Peng P. Ovarian fibrosarcoma: A single-institution experience and a review of the literature. Journal of Ovarian Research 2020; 13(1):1-8.
  3. Parwate NS, Patel SM, Arora R, Gupta M. Ovarian fibroma: A clinico-pathological study of 23 cases with review of literature. The Journal of Obstetrics and Gynecology of India 2016; 66:460-5.
  4. Irving JA, Alkushi A, Young RH, Clement PB. Cellular fibromas of the ovary: a study of 75 cases including 40 mitotically active tumors emphasizing their distinction from fibrosarcoma. The American journal of surgical pathology 2006; 30(8):929-38.
  5. Omori M, Kondo T, Fukushima J, Oi M, Watanabe Y, Nakazawa T, et al. Extraovarian fibroma with minor sex cord elements: a case report and literature review. International Journal of Surgical Pathology 2017; 25(5):472-6.
  6. Bucella D, Limbosch JF, Buxant F, Simon P, Fayt I, Anaf V, et al. Recurrence of mitotically active cellular fibroma of the ovary. Obstetrics and gynecology international 2009; 2009.
  7. Monteiro SB, Costa A, Paiva V. Mitotically active cellular ovarian fibroma with Meigs’ syndrome and elevated CA-125: towards fertility preservation. Journal of pediatric and adolescent gynecology 2012; 25(5):e107-9.
  8. Aram S, Moghaddam NA. Bilateral ovarian fibroma associated with Gorlin syndrome. Journal of Research in Medical Sciences: The Official Journal of Isfahan University of Medical Sciences 2009; 14(1):57-61.
  9. Sharmila V, Saichandran S, Babu TA, Singh D. A rare case of bilateral ovarian fibroma presenting as Meigs syndrome. Journal of Obstetrics and Gynaecology 2013; 33(6):636-7.
  10. Mandal S, Mahajan D, Roy S, Singh M, Khurana N. Fibroma with minor sex cord elements–an incidental finding in a normal sized ovary A case report with literature review. Diagnostic Pathology 2007; 2(1):1-4.
  11. Yıldırım N, Saatli B, Akalın F, Ulukuş Ç, Obuz F, Saygılı U. Mitotically active cellular fibroma of the ovary: A case report. Turkish Journal of Obstetrics and Gynecology 2015; 12(1):53-5.
  12. Kim JY, Na K, Kim HS. Clinicopathological characteristics of mitotically-active cellular fibroma of the ovary: a single-institutional experience. Anticancer research 2017; 37(5):2557-64.